This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Risk Prediction in Type II Diabetics With Ischemic Heart Disease

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2014 by Axel Bauer, Thebiosignals.com.
Recruitment status was:  Recruiting
Sponsor:
Information provided by (Responsible Party):
Axel Bauer, Thebiosignals.com
ClinicalTrials.gov Identifier:
NCT01422057
First received: August 9, 2011
Last updated: February 5, 2014
Last verified: February 2014
August 9, 2011
February 5, 2014
January 2010
January 2014   (Final data collection date for primary outcome measure)
Major cardiovascular event [ Time Frame: 2 years ]
Combination of total mortality, non-fatal myocardial infarction and non-fatal stroke
Same as current
Complete list of historical versions of study NCT01422057 on ClinicalTrials.gov Archive Site
  • Cardiovascular mortality [ Time Frame: 2 years ]
  • sudden cardiac death [ Time Frame: 2 years ]
  • Total mortality [ Time Frame: 2 years ]
Same as current
Not Provided
Not Provided
 
Risk Prediction in Type II Diabetics With Ischemic Heart Disease
Risk Prediction in Type II Diabetics With Ischemic Heart Disease by Cardiac Autonomic Function
The purpose of this study is to test whether cardiac autonomic dysfunction predicts is a prognostic marker in type-2 diabetics with ischemic heart disease

In patients with type 2-diabetes and ischemic heart disease autonomic function might be seriously affected.

In the present study, markers of cardiac autonomic dysfunction, repolarization and respiration abnormalities will be assessed from Holter recordings and 30-minute recordings of high-resolution three dimensional ECG, non-invasive arterial blood pressure and respiratory activity.

The correlation between markers of cardiac autonomic dysfunction and markers of severity of type-2 diabetes will be assessed. Autonomic dysfunction is assumed present when both heart rate turbulence and deceleration capacity are abnormal ("severe autonomic failure"). Assessment of severity of diabetes includes levels of HbA1c and urine albumine, duration and treatment of diabetes, and diabetes related complications (nephropathy, neuropathy, retinopathy).

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Consecutive patients with diagnose of ischemic heart disease and type-2 diabetes are included.
  • Type-2 Diabetes Mellitus
  • Ischemic Heart Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
500
January 2016
January 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • type-2 diabetes
  • coronary artery disease

Exclusion Criteria:

  • age >80 years
  • acute coronary syndrome
  • life expectancy <1 year
  • unable to give informed consent
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01422057
402/2009BO2-2
No
Not Provided
Not Provided
Not Provided
Axel Bauer, Thebiosignals.com
Thebiosignals.com
Not Provided
Not Provided
Thebiosignals.com
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP